Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 1—January 2016
Dispatch

Severe Community-Acquired Bloodstream Infection with Acinetobacter ursingii in Person who Injects Drugs

Helmut J.F. Salzer, Thierry Rolling, Stefan Schmiedel, Eva-Maria Klupp, Christoph Lange, and Harald SeifertComments to Author 
Author affiliations: University Medical Center Hamburg–Eppendorf, Hamburg, Germany (H.J.F. Salzer, T. Rolling, S. Schmiedel, E.-M. Klupp); Research Center Borstel, Sülfeld, Germany (H.J.F. Salzer, C. Lange); Karolinska Institute, Stockholm, Sweden (C. Lange); University of Namibia School of Medicine, Windhoek, Namibia (C. Lange); German Center for Infection Research, Braunschweig, Germany (C. Lange, H. Seifert); University of Cologne, Cologne, Germany (H. Seifert)

Main Article

Table

Characteristics of 16 patients with Acinetobacter ursingii bloodstream infections*

Patient, age†/sex Immune status Clinical manifestation Acquisition Treatment Outcome Reference
63 y/M Compromised Catheter-related bactemia Nosocomial Imipenem, amikacin, rifampin Survived (3)
99 y/M Competent Bacteremia, cholangitis Nosocomial NR NR (8)
67 y/F Competent Bacteremia, septic shock Nosocomial NR NR (8)
38 y/F Compromised Bacteremia Nosocomial NR NR (8)
38 wk/M (newborn) NR Wet lung, bacteremia Nosocomial Meropenem, amikacin Survived (5)
23 wk/M (newborn) NR Premature, ARDS, bacteremia Nosocomial Meropenem, amikacin Died (5)
37 wk/F (newborn) NR Hypoxic ischemic encephalopathy, bacteremia Nosocomial Meropenem, amikacin Survived (5)
32 wk/F (newborn) NR Premature, ARDS, bacteremia Nosocomial Meropenem, amikacin Survived (5)
25 wk/M (newborn) NR Premature, ARDS, intracranial hemorrhage, bacteremia Nosocomial Meropenem, amikacin Died (5)
36 wk/M (newborn) NR Premature, necrotizing enterocolitis, bacteremia Nosocomial Ceftazidime, amikacin, immunoglobulin Survived (6)
29 wk/F (newborn) NR Premature, necrotizing enterocolitis, severe hypoxia, bacteremia Nosocomial Ciprofloxacin, piperacillin Died (6)
31 wk/F (newborn) NR Premature, ARDS, necrotizing enterocolitis, bacteremia Nosocomial Netilmicin, clindamycin;‡ teicoplanin, cefotaxim, clindamycin;§ tobramycin, ciprofloxacin;¶ piperacillin/ tazobactam, vancomycin# Survived (6)
26/F** Competent Bacteremia Nosocomial Piperacillin Survived (4)
30/F** Competent Bacteremia Nosocomial Cefepime Survived (4)
NR/NR Compromised Bacteremia Nosocomial Ciprofloxacin†† Survived (9)
47/F Competent Bacteremia, severe sepsis Community Meropenem Survived This study

*NR, not reported; ARDS, acute respiratory distress syndrome.
†Age for the 8 newborns is gestational age.
‡First treatment.
§Second treatment.
¶Third treatment.
#Fourth treatment.
**These women were pregnant.
††Infected with a carbapenem-resistant strain.

Main Article

Page created: December 18, 2015
Page updated: December 18, 2015
Page reviewed: December 18, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external